There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intellia Therapeutics (NTLA – Research Report), Tandem Diabetes Care (TNDM – Research Report) and Tarsus Pharmaceuticals (TARS – Research Report) with bullish sentiments.
Intellia Therapeutics (NTLA)
In a report released yesterday, Gena Wang from Barclays reiterated a Buy rating on Intellia Therapeutics, with a price target of $76.00. The company’s shares closed last Thursday at $27.18.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $67.80 average price target, representing a 155.8% upside. In a report issued on February 15, Canaccord Genuity also maintained a Buy rating on the stock with a $72.00 price target.
See today’s best-performing stocks on TipRanks >>
Tandem Diabetes Care (TNDM)
In a report released yesterday, Matt Miksic from Barclays maintained a Buy rating on Tandem Diabetes Care, with a price target of $39.00. The company’s shares closed last Thursday at $25.00.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tandem Diabetes Care with a $31.30 average price target, which is a 27.8% upside from current levels. In a report issued on February 16, Lake Street also maintained a Buy rating on the stock with a $60.00 price target.
Tarsus Pharmaceuticals (TARS)
Barclays analyst Balaji Prasad reiterated a Buy rating on Tarsus Pharmaceuticals yesterday and set a price target of $40.00. The company’s shares closed last Thursday at $31.54, close to its 52-week high of $31.84.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of
Currently, the analyst consensus on Tarsus Pharmaceuticals is a Strong Buy with an average price target of $52.00, a 73.3% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NTLA:
- NTLA Upcoming Earnings Report: What to Expect?
- Intellia Therapeutics price target lowered to $24 from $38 at Baird
- Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
- Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
- Intellia Therapeutics, ReCode Therapeutics announce collaboration
